kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
4,125
JPY
-5
(-0.12%)
Feb 6, 3:30 pm JST
26.29
USD
Feb 6, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
67.9
PBR
1.07
Yield
4.61%
Margin Trading Ratio
6.68
Stock Price
Feb 6, 2026
Opening Feb 6, 9:00 am
4,110 JPY 26.21 USD
Previous Close Feb 5
4,130 JPY 26.31 USD
High Feb 6, 11:16 am
4,140 JPY 26.40 USD
Low Feb 6, 9:01 am
4,095 JPY 26.13 USD
Volume
122,800
Trading Value
0.51B JPY 3.23M USD
VWAP
4121.74 JPY 26.27 USD
Minimum Trading Value
412,500 JPY 2,629 USD
Market Cap
0.18T JPY 1.17B USD
Number of Trades
283
Liquidity & Number of Trades
As of Feb 6, 2026
Liquidity
Slightly High
1-Year Average
608
1-Year High Apr 9, 2025
2,521
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 30, 2026 29,600 87,800 2.97
Jan 23, 2026 27,900 85,900 3.08
Jan 16, 2026 23,400 97,300 4.16
Jan 9, 2026 23,100 82,700 3.58
Dec 26, 2025 26,300 58,600 2.23
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."